This study is a phase 3 study where eligible patients will be randomized 1:1 to one of two treatment strategies: receiving a thrombopoietin receptor agonist (Avatrombopag), or anti-CD20 (Rituximab).
Phase:
PHASE3
Details
Lead Sponsor:
Ostfold Hospital Trust
Collaborators:
Haukeland University Hospital Helse Fonna Helse Nord-Trndelag HF Helse Stavanger HF Nordlandssykehuset HF Oslo University Hospital Sorlandet Hospital HF St. Olavs Hospital Sykehuset i Vestfold HF University Hospital of North Norway University Hospital, Akershus